Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
References (47)
- et al.
Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double- blind, placebo-controlled European study
J Infect
(2000) - et al.
In vitro selection and charac- terisation of influenza B/Beijing/I/ 87 isolates with altered susceptibili- ty to zanamivir
Virology
(1999) Fixing the number of events in large comparative trials with low event rates: A binomial approach
Control Clin Trials
(1993)- et al.
Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population
J Am Med Dir Assoc
(2005) Resistance of influenza viruses to neuraminidase inhibitors-a review
Antiviral Res
(2000)- et al.
Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase
Structure
(1998) - et al.
Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Morb Mortal Wkly ReD
(2006) - et al.
Influenza- associated hospitalizations in the United States
JAMA
(2004) - et al.
Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985
AmJ Pubfic Health
(1987)
4-Guanidino-2,4- dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor of both the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
Antimicrob Agents Chemother
2,3-Didehydro-2,4-dideoxy-4- guanidino-N-acetyI-D neuraminic acid (4-guanidino- NeuSAc2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus
Biochem Mol Biol Int
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir
Antimicrob Agents Chemother
Efficacy of zanamivir against avian influenza A viruses that possess genes encoding HSN1 internal proteins and are pathogenic in mammals
Antimicrob Agents Chemother
Neuraminidase inhibitors for influenza
N Engl J Med
Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis
J Antimicrob Chemother
Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections [published corrections appear in Lancet. 1999;353:504 and Lancet. 1999;353: 1104]
Lancet
Zanamivir For treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial
J Pediatr Infect Dis
Inhaled zanamivir for the prevention of influenza in families
N Engl J Med.
Zanamivir prophylaxis: An effective strategy for the prevention of influenza types A and B within households
J Infect Dis
Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
JAMA
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects
Primaryisolation of viruses
Cited by (45)
Lessons from resistance analysis in clinical trials of IV zanamivir
2023, Virus ResearchCombined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir
2018, European Journal of PharmacologyInhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
2015, Advanced Drug Delivery ReviewsCitation Excerpt :Treatment should be initiated as soon as possible following symptom onset, ideally within 48 h [178,183]. Clinical trials have shown that adherence to these treatment windows significantly reduces the duration of illness, symptom severity and the rate of influenza associated complications [181,183–186]. In a comparative study, it was shown that treatment with inhaled zanamivir was more effective than oral oseltamivir in reducing symptom severity in patients infected with either influenza A or B viruses [187].
Management of influenza infection in solid-organ transplant recipients:consensus statement of the group for the study of infection in transplantrecipients (GESITRA) of the spanish society of infectious diseases and clinicalmicrobiology (SEIMC) and the spanish network for research in infectiousdiseases (REIPI)
2013, Enfermedades Infecciosas y Microbiologia ClinicaCitation Excerpt :Preexposure chemoprophylaxis has been studied in the community in groups of healthy adults and patients living in institutional centers who received antiviral medications during influenza virus season. The efficacy of zanamivir and oseltamivir in preventing febrile, laboratory-confirmed influenza illness was 84% and 82%, respectively.27,35,36 Preexposure chemoprophylaxis must be administered only for the duration of the exposure.
Neuraminidase inhibition improves endothelial function in diabetic mice
2023, American Journal of Physiology - Endocrinology and Metabolism